CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species” Apr 12, 2022 8:30am EDT
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program Mar 30, 2022 5:00pm EDT
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab Jan 25, 2022 6:06pm EST
